Reductions in Lipoprotein Particle Concentration Shown in Patients With Severe (≥500 mg/dL) Hypertriglyceridemia
BEDMINSTER, N.J., and DUBLIN, Ireland, Aug. 28, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that additional data from its pivotal MARINE Phase 3 clinical trial are now available electronically through the Journal of Clinical Lipidology and are expected to be published in a future print issue of the journal before the end of 2012.
The publication, titled "AMR101, a Pure EPA Omega-3 Fatty Acid: Effects on Lipoprotein Particle Concentration and Size in Patients with Very High Triglyceride Levels (the MARINE Study)," reports the effects of Vascepa™ (icosapent ethyl) capsules (formerly referred to as AMR101) on lipoprotein particle concentrations and sizes in patients with baseline triglyceride levels ≥500 mg/dL. This publication reported that Vascepa significantly reduced median concentrations of large very-low-density lipoprotein (VLDL), total LDL, small LDL and total high-density lipoprotein (HDL) particles and reduced VLDL particle size in a patient population with TG ≥500 mg/dL. Vascepa did not significantly change the overall sizes of LDL or HDL particles.The MARINE trial was a Phase 3, multicenter, placebo-controlled, randomized, double-blind, 12-week study. The study enrolled 229 patients and investigated Vascepa as a treatment for severe (TG ≥500 mg/dL) hypertriglyceridemia. The MARINE trial achieved its primary efficacy endpoints as defined in the clinical trial protocol and demonstrated a favorable safety profile. "Vascepa showed significant improvements in several biomarkers of cardiovascular health," stated Harold Bays, M.D., Medical Director of Louisville Metabolic and Atherosclerosis Research and principal investigator of the MARINE trial. "In this follow-up analysis of the MARINE trial, Vascepa reduced both total and small LDL particle concentration, which is consistent with its known effects in decreasing Apo B and lack of LDL-cholesterol raising in patients with severely high triglyceride levels."
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV